![VitaDX logo - Diagnostics for life]

Rennes and Paris, November 9, 2017,

VitaDX International appoints Arnaud BUTZBACH as an independent board member

VitaDX, a company specialized in cancer diagnostic strengthens its board of directors by appointing Arnaud BUTZBACH as an independent board member.

Arnaud co-founded MEDIAN Technologies (EuroNext: ALMDT) a company providing innovative imaging software solutions and services with a focus on oncology, back in 2002. As the CTO, VP Operations and CIO, Arnaud has been instrumental in reaching the scientific, technical, regulatory, operational and financial milestones leading to success in this industry since the inception of the company in 2002. Leveraging a long experience in the medical imaging and medical robotics industries, Arnaud supports the development of innovative companies with a strong potential (HalioDX, Ekinnox). He has also been independent board member at Axilum Robotics.

Arnaud Butzbach graduated from the National Superior Engineering School for Computer Science and Applied Mathematics of the National Polytechnic Institute of Grenoble (ENSIMAG/INPG).

VitaDX will benefit from his know-how and expertise in image processing, algorithmic, software engineering and information systems in the medical field for the development of its products primarily for VisioCyt®, a solution for the early diagnostic of bladder cancers.

The VitaDX board of directors, chaired by Jacques le Bozec, now comprises six directors with complementary and synergetic profiles, creating an optimal environment for VitaDX to orient its strategy and support its growth.

Allan Rodriguez, VitaDX 's CEO declares « We are very happy that Arnaud accepted to join our board of directors. He will bring his know-how in artificial intelligence applied to medical diagnostic and his experience in structuring high potential technology companies."

« Supporting VitaDX in providing innovative solutions for the detection and diagnostic of cancers is an exceptional opportunity », added Arnaud Butzbach. « especially when the team is so promising and imaging plays a key role ...»

About VitaDX

VitaDX International SA was founded in April 2015 to exploit research carried out over the past 10 years within the Paris Hospitals (Hôpitaux de l'Assistance Publique-Hôpitaux de Paris, AP-HP), the South-Paris University and the CNRS, with the objective of becoming a major player in early cancer diagnostics by exploiting fluorescence, image processing and Artificial Intelligence, specifically Deep Learning. The company is supported by the SATT Paris-Saclay as part of a collaboration with the ONERA (French Aerospace Lab) for the development of the image processing algorithms. Over 2 years after its creation, the VitaDX team is made up of 13 people working on the development of the company, in two locations: Rennes and Paris. VitaDX is in the clinical trial stage since January 2017, in collaboration with several renown hospital centers. Following a first fundraising of 1.2M€ in July 2015, VitaDX has recently raised 1.6M€ through GO CAPITAL Amorçage II and AURIGA IV Bioseeds and two private investors.

Contacts

Allan RODRIGUEZ, CEO of VitaDX: +33 6.98.46.34.68 ; allan@vitadx.com
Arnaud BUTZBACH, independent board member: +33 6.22.46.82.46 ; iimaging@butzbach.org